- Home
- LXEH vs NNVC Comparison
LXEH vs NNVC Comparison
Compare LXEH & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- NNVC
- Stock Information
- Founded
- LXEH 2001
- NNVC 2005
- Country
- LXEH China
- NNVC United States
- Employees
- LXEH N/A
- NNVC N/A
- Industry
- LXEH Other Consumer Services
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- NNVC Health Care
- Exchange
- LXEH Nasdaq
- NNVC Nasdaq
- Market Cap
- LXEH 25.1M
- NNVC 24.4M
- IPO Year
- LXEH 2020
- NNVC N/A
- Fundamental
- Price
- LXEH $1.37
- NNVC $1.23
- Analyst Decision
- LXEH
- NNVC
- Analyst Count
- LXEH 0
- NNVC 0
- Target Price
- LXEH N/A
- NNVC N/A
- AVG Volume (30 Days)
- LXEH 197.7K
- NNVC 213.1K
- Earning Date
- LXEH 04-30-2025
- NNVC 05-15-2025
- Dividend Yield
- LXEH N/A
- NNVC N/A
- EPS Growth
- LXEH N/A
- NNVC N/A
- EPS
- LXEH N/A
- NNVC N/A
- Revenue
- LXEH $4,493,795.00
- NNVC N/A
- Revenue This Year
- LXEH N/A
- NNVC N/A
- Revenue Next Year
- LXEH N/A
- NNVC N/A
- P/E Ratio
- LXEH N/A
- NNVC N/A
- Revenue Growth
- LXEH N/A
- NNVC N/A
- 52 Week Low
- LXEH $1.49
- NNVC $0.94
- 52 Week High
- LXEH $50.08
- NNVC $2.55
- Technical
- Relative Strength Index (RSI)
- LXEH 33.37
- NNVC 36.88
- Support Level
- LXEH $1.49
- NNVC $1.36
- Resistance Level
- LXEH $1.85
- NNVC $1.46
- Average True Range (ATR)
- LXEH 0.15
- NNVC 0.09
- MACD
- LXEH 0.15
- NNVC -0.03
- Stochastic Oscillator
- LXEH 15.38
- NNVC 19.05
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.